Bispecific T-cell engagers (BiTEs) are a new type of treatment for relapsed or refractory multiple myeloma (RRMM). Here are some key points about BiTE therapy:

- Administration: BiTEs are given by intravenous infusions or subcutaneous injections. For example, teclistamab-cqyv is administered as a subcutaneous injection Show Full Answer

Bispecific T-cell engagers (BiTEs) are a new type of treatment for relapsed or refractory multiple myeloma (RRMM). Here are some key points about BiTE therapy:

- Administration: BiTEs are given by intravenous infusions or subcutaneous injections. For example, teclistamab-cqyv is administered as a subcutaneous injection with increasing doses over seven days, followed by weekly injections.
- Effectiveness: Research shows BiTEs are effective for treating RRMM. The FDA approved teclistamab-cqyv in 2022 for people who have been treated with at least three other lines of therapy.
- Mechanism: BiTEs are monoclonal antibodies that bind to two different proteins, CD3 on T cells and a specific protein on myeloma cells, helping the immune system destroy cancer cells.
- Side Effects: Common side effects include fever, fatigue, cytokine release syndrome (CRS), pain at the injection site, nausea, headache, diarrhea, pneumonia, and low blood cell counts.

If you or a loved one is considering BiTE therapy, it's important to discuss the potential risks and benefits with your myeloma specialist.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment | MyMyelomaTeam

What Is BCMA-Targeted Immunotherapy for Multiple Myeloma? | MyMyelomaTeam